Global Gastroparesis Drugs
Market Report
2025
Gastroparesis Drugs Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Gastroparesis Drugs Market Report 2024.
Global Gastroparesis Drugs Market Report 2024 Market Size Split by Drug Type (Antiemetic Agents, Prokinetic Agents, Botulinum Toxin Injections), by End-User (Hospitals, Clinics, Pharmacies), by Dise...
According to Cognitive Market Research, The Gastroparesis Drugs Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Asia Pacific accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Gastroparesis Drugs Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Drug Type |
|
| Market Split by End-User |
|
| Market Split by Disease Type |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Gastroparesis Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Gastroparesis Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Gastroparesis Drugs Market Report Description
Introduction of The Gastroparesis Drugs Market
Gastroparesis means paralysis of the stomach. It’s a functional disorder affecting your stomach nerves and muscles. It makes your stomach muscle contractions weaker and slower than they need to be to digest your food and pass it on to your intestines. This leads to food sitting too long in your stomach. Symptoms include nausea, vomiting, abdominal pain, feeling full soon after beginning to eat (early satiety), abdominal bloating, and heartburn. Medications to treat gastroparesis may include metoclopramide (Reglan) and erythromycin. Medications to control nausea and vomiting include diphenhydramine (Benadryl, others) and ondansetron (Zofran). Prochlorperazine (Compro).
The market is expected to grow due to several factors, including rising healthcare costs, growing government support for gastroparesis management, growing awareness of gastroparesis and available treatment options, rising numbers of R&D activities for novel gastroparesis drugs, and advancements in diagnostic technologies. The global market for gastroparesis drugs is expected to grow at a faster rate due to the introduction of novel drug delivery systems, the development of better healthcare facilities and infrastructure, and the rising demand for safe and effective medications to treat the symptoms of gastroparesis.
Gastroparesis Drugs Market Size
Market Dynamics of The Gastroparesis Drugs Market
Key Drivers for The Gastroparesis Drugs Market
- An increasing prevalence of gastroparesis disorder propels the growth of the gastroparesis drugs market.
The rising prevalence of gastroparesis, a disorder characterized by delayed stomach emptying, is driving the growth of the gastroparesis drug market. More than 50% of cases of gastroparesis are idiopathic; diabetic, postsurgical, and post-infectious causes are common. This increase in prevalence, attributed to factors like lifestyle changes, rising obesity rates, and a growing aging population, has spurred pharmaceutical companies to develop and introduce innovative treatments for managing symptoms and improving patients' quality of life. As awareness about gastroparesis grows and diagnosis rates improve, the demand for effective medications to alleviate symptoms such as nausea, vomiting, and abdominal pain is expected to fuel market expansion further.
For instance, in October 2021 as per an American Gastroenterological Association (AGA), Standardized disease prevalence was 267.7 per 100,000 persons, whereas the prevalence of “definite” gastroparesis (individuals diagnosed within 3 months of gastric emptying scintigraphy testing with persistent symptoms for more than 3 months) was 21.5 per 100,000 persons. The most common etiologies were diabetic (57.4%; type 1 [5.7%], type 2 [51.7%]), postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%).
Source:(https://www.gastrojournal.org/article/S0016-5085(21)03613-1/fulltext)
For instance, in 2022, according to a research article by United European Gastroenterology Journal, a Netherlands-based online publisher of research articles, in 2021 the overall prevalence rate of gastroparesis was 267.7 per 100,000 persons in the US. The prevalence rate of definite gastroparesis was 21.5 per 100,000 persons. As a result, the increasing prevalence of gastroparesis is driving the growth of gastroparesis treatment.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557951/)
Therefore, the increasing prevalence of gastroparesis creates a need to treat gastroparesis disorder and increases demand for gastroparesis drugs driving the growth of the market.
- An increasing incidence of diabetes boosts the market for gastroparesis drugs.
The global cases of diabetes are increasing at a rapid pace. Type 1 diabetes is more closely associated with gastroparesis, while those with type 2 diabetes have a significantly greater prevalence of gastroparesis. Consequently, gastroparesis associated with type 2 diabetes is seen more often. Since diabetes is a common cause of gastroparesis, the number of instances of the illness is directly impacted by the rise in diabetes cases. Thus, the primary driver of market expansion is the rising prevalence of diabetes.
For instance, in 2021, according to the IDF Diabetes Atlas approximately 537 million adults (20-79 years) are living with diabetes - 1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. In addition, the growing incidence of Type 1 and Type 2 diabetes increases the condition of gastroparesis significantly.
Source:(https://diabetesatlas.org/#:~:text=537%20million%20adults%20(20%2D79,2021%20%2D%201%20every%205%20seconds.)
Therefore, as the cases of diabetes increase due to an unhealthy lifestyle, poor diet, excess of unhealthy fat, and low dietary fiber along with a decrease in physical activity hence leads to an increase in demand for gastroparesis treatment and propels the gastroparesis drugs market.
Restraint Factor for The Gastroparesis Drugs Market
- Serious side effects of gastroparesis drugs restrain the market growth.
One major factor preventing the gastroparesis pharmaceutical sector from growing is the existence of serious side effects linked to the drugs used to treat it. Prokinetics, a class of medications that improve gastrointestinal motility, is the first line of treatment for gastroparesis. Moreover, metoclopramide belongs to a particular class of drugs called prokinetic medicines. Notably, metoclopramide is the only medication that the US Food and Medicine Administration (FDA) has approved for the treatment of gastroparesis. It is meant to lessen reflux, hasten the emptying of the stomach, and ease nausea and vomiting. Serious side effects including Tardive Dyskinesia and Neuroleptic Malignant Syndrome are possible outcomes of using it. In addition, a more modern medication known as domperidone has a lower rate of negative side effects. However, access limitations limit its availability.
Furthermore, a medication called Ozempic, Wegovy, and Mounjaro, is used to treat diabetes, and obesity and is useful for weight loss. New research finding states that Ozempic, Wegovy are linked to cases of stomach paralysis. The drug makers Novo Nordisk and Eli Lilly failed to adequately warn patients about the possible risk of severe stomach problems associated with their blockbuster drugs Ozempic and Mounjaro, according to a lawsuit filed in 2023
However, the use of Ozempic, Wegovy, and Mounjaro can lead to adverse events such as severe gastroparesis (paralyzed stomachs), abdominal pain, stomach pain, severe vomiting, gastrointestinal events, bowel obstruction, and other potential side effects.
For instance, in July 2023 FDA said it had received reports of some patients taking semaglutide — Ozempic and Wegovy drug used to treat diabetes and weight loss — experiencing severe gastroparesis, or "stomach paralysis," in which digestion of food slows significantly, potentially causing severe vomiting and nausea.
Source:(https://www.advisory.com/daily-briefing/2023/07/27/stomach-paralysis)
Therefore, the most common side effects are headaches, lethargy, constipation, diarrhea, cramping in the abdomen, and sleepiness. Therefore, during the anticipated forecast period, the side effects of gastroparesis drugs would restrain market growth.
How did COVID-19 impact the Gastroparesis Drugs Market
In patients with chronic gastrointestinal illnesses, the emergence of COVID-19 initially posed significant challenges due to historical associations between viruses and complications in gastrointestinal disorders, such as gastroparesis. COVID-19's impact on these patients was multifaceted, ranging from exacerbating existing symptoms to potentially inducing new complications. Managing these cases requires a careful balance between addressing COVID-19-related concerns and managing underlying gastrointestinal conditions. Additionally, the pandemic highlighted the importance of further research into the interactions between viral infections and chronic gastrointestinal illnesses to better understand and manage such complexities in patient care.
For instance, in December 2022 according to an article published by PubMed, The COVID-19 pandemic has had a profound impact on the endoscopy department, characterized by a consistent reduction of upper and lower GI procedures, as well as a more modest reduction of ERCPs. Therefore, gastrointestinal endoscopic procedure declines and rising gastroparesis consequences greatly influence market growth. But as the epidemic has since decreased, the market under investigation is anticipated to develop steadily during the study's projection period.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833369/)
Moreover, according to the 2020 annual report of EVOKE PHARMA, a biotechnology company, due to the restrictions imposed as a result of the COVID-19 pandemic, such as lockdown, its sales force has been restricted from conducting in-person interactions with certain physicians and customers. It has been restricted to conducting educational and promotional activities for Gimoti, indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The continued spread of COVID-19 and the measures taken by the governments of the countries affected disrupted the raw material supply chain and the manufacturing or shipment of Gimoti for commercial sale which could harm the business, financial condition, and results of operations.
Source:(https://investor.evokepharma.com/node/9416/pdf)
Opportunities for The Gastroparesis Drugs Market
- Research and development efforts to treat gastroparesis may represent a significant opportunity to drive the market.
The growing demand for the treatment of gastroparesis propels research and development in the pharmaceutical industry, leading to the introduction of novel drugs to address the symptoms and underlying causes of gastroparesis. Gastroparesis condition is characterized by impaired stomach emptying, leading to symptoms of nausea and vomiting. Therefore, these research and development advancements propel the market expansion of gastroparesis drugs.
For instance, in March 2024 Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company focused on developing groundbreaking medications for patients suffering from gastrointestinal (GI) disorders, and its European partner, Dr. Falk Pharma GmbH (Dr. Falk Pharma), is pleased to announce that FDA has granted clearance for the Investigational New Drug (IND) application for naronapride, a treatment for patients with gastroparesis.
Source:(https://www.biospace.com/article/releases/renexxion-ireland-ltd-and-dr-falk-pharma-gmbh-announce-fda-clearance-of-the-investigational-new-drug-application-for-naronapride-to-treat-gastroparesis-and-subsequent-expansion-of-the-ongoing-phase-2b-move-it-study-to-the-united-states/)
For instance, in October 2023, Enterra Medical, Inc., an innovator in treatments for people living with gastroparesis, announced today that the Enterra II System has been granted MR Conditional approval from the United States Food and Drug Administration (FDA).
Source:(https://www.enterramedical.com/newsroom/enterra-ii-system-an-advanced-treatment-for-gastroparesis-receives-fda-approval-for-mr-conditional-use/)
Therefore, the introduction of novel drugs through research and development which are effective in providing treatment benefits boosts the growth of the gastroparesis drug market.
We have various report editions of Gastroparesis Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Gastroparesis Drugs Market
Companies are implementing strategies such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to sustain in the market. Pharmaceutical firms are always working to enhance their medications' effectiveness, safety, motility, and affordability for the treatment of gastroparesis. Additionally, Companies want approval of their product by government organizations like the US FDA and the European Medicines Agency.
For instance, in March 2024 – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company focused on developing groundbreaking medications for patients suffering from gastrointestinal (GI) disorders, and its European partner, Dr. Falk Pharma GmbH (Dr. Falk Pharma), is pleased to announce that FDA has granted clearance for the Investigational New Drug (IND) application for naronapride, a treatment for patients with gastroparesis.
Source:(https://www.biospace.com/article/releases/renexxion-ireland-ltd-and-dr-falk-pharma-gmbh-announce-fda-clearance-of-the-investigational-new-drug-application-for-naronapride-to-treat-gastroparesis-and-subsequent-expansion-of-the-ongoing-phase-2b-move-it-study-to-the-united-states/)
Top Companies Market Share in Gastroparesis Drugs Industry: (In no particular order of Rank)
- Medtronic
- Kimberly-Clark Corporation
- Abbott Laboratories
- Salix Pharmaceuticals
- Inc
- Boston Scientific Corporation
- C. R. Bard
- Inc
- Janssen Global Services LLC
- Cardinal Health
- Inc.
- Alfa Wassermann SPA
- Evoke Pharma
- Rhythm Pharmaceuticals
- Inc.
- Kimberly-Clark Corporation
- Abbott Laboratories
- Salix Pharmaceuticals
- Inc
- Boston Scientific Corporation
- C. R. Bard
- Inc
- Janssen Global Services LLC
- Cardinal Health
- Inc.
- Alfa Wassermann SPA
- Evoke Pharma
- Rhythm Pharmaceuticals
- Inc
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of The Gastroparesis Drugs Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North American region dominated the gastroparesis drug market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. The North American market is expanding largely due to the high prevalence of gastroparesis in the region, the accessibility of specialist gastroenterology clinics, the availability of modern healthcare infrastructure, and the rising awareness and diagnosis of gastroparesis. Favorable reimbursement rules for gastroparesis medications and related therapies, together with the strong presence of major pharmaceutical firms engaged in research and development, further accelerate the growth rate of the North American market.
Due to a sizable population of prediabetes, advantageous reimbursement practices, and increased public awareness of the illness, the United States led the market.
For instance, according to the data from the CDC in May 2024, 97.6 million people aged 18 years or older have prediabetes (38.0% of the adult United States population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also responsible for the dominance of the region in the market.
Source:(https://www.cdc.gov/diabetes/php/data-research/index.html)
Which Region Is Expanding at The Fastest CAGR?
The Europe region's gastroparesis drug market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. The main factors driving the growth of the European market are the rising incidence of diabetes and underlying gastrointestinal problems, the rising number of improvements in the healthcare system, and the establishment of specialty clinics for the treatment of gastroparesis. The European gastroparesis drug market is expected to grow at a faster rate due to factors such as the increasing investments in research and development of drugs related to gastroparesis, the emphasis on patient-centric care and improving the quality of life for patients with the disease, and the favorable government initiatives that support the diagnosis and treatment of gastroparesis.
For instance, in February 2023, Renexxion Ireland announced the start of a Phase IIb trial of gastroparesis therapy. This trial has been mainly designed to assess the safety, tolerability, and efficacy of naronapride among gastroparesis patients. It will further help in the development of new drugs for gastroparesis.
Source:(https://www.clinicaltrialsarena.com/news/renexxion-ireland-gastroparesis-therapy/)
The current report Scope analyzes Gastroparesis Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Gastroparesis Drugs Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Gastroparesis Drugs Market Analysis
Global Gastroparesis Drugs Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Gastroparesis Drugs Industry growth. Gastroparesis Drugs market has been segmented with the help of its Drug Type, End-User Disease Type , and others. Gastroparesis Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Gastroparesis Drugs Market
Drug Type Segment Analysis
By drug class, the prokinetic agent's segment accounted for the highest share in the global gastroparesis drugs market due to the drug's ability to improve gastrointestinal motility, treat delayed stomach emptying, and relieve patients' symptoms; as a result, both patients and healthcare professionals have adopted these drugs widely. Prokinetic medicines are a class of medications that increase the contraction of the stomach muscles, hence improving the stomach's general mobility. Patients with gastroparesis, which impairs digestion and induces symptoms like nausea and vomiting, are often administered them. Because prokinetic medicines can address the underlying cause of the ailment, they are regarded as a cornerstone in the treatment of gastroparesis. These medications have not only been used to treat gastroparesis but have also been investigated for their safety and efficacy in critically ill patients undergoing enteral nutrition, with encouraging findings in lowering feeding intolerance in these patients.
For instance, in December 2023, The US Food and Drug Administration (FDA) accepted the new drug application (NDA) filed by Vanda Pharmaceuticals for its drug tradipitant to treat gastroparesis.
Source:(https://www.pharmaceutical-technology.com/news/fda-vanda-gastroparesis-treatment/)
Gastroparesis Drugs Market Share (%) by Drug Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gastroparesis Drugs Industry. Request a Free Sample PDF!
End-User Segment Analysis
By end-user, the hospital sector accounted for the largest revenue-generating share in the gastroparesis drugs market as hospitals are equipped with main healthcare facilities, where a significant proportion of gastroparesis diagnoses are established and patients receive complete medical care. The complex and varied demands of gastroparesis patients, including severe instances that can necessitate surgical treatments or specialized care, can be handled by hospitals with the resources and medical knowledge they need. A major factor in the hospital segment's market dominance is its comprehensive strategy and capacity for providing integrated care.
For instance, a research study published in PubMed states that Gastroparesis (GP) is commonly seen in hospitalized patients. Refractory vomiting and related dehydration, electrolyte abnormalities, and malnutrition are indications for hospital admission. In addition, tube-feeding intolerance is a common sign of gastric dysmotility in critically ill patients. Thus the growing need for hospitalization makes Hospitals the dominant segment in generating the largest market share.
Source:(https://pubmed.ncbi.nlm.nih.gov/33336872/#:~:text=Gastroparesis%20(GP)%20is%20commonly%20seen,dysmotility%20in%20critically%20ill%20patients.)
Gastroparesis Drugs Market Share (%) by End-User in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Gastroparesis Drugs Disease Type Segment Analysis
Disease Type Segment Analysis
By disease type, the diabetic gastroparesis segment accounted for the highest share in the global gastroparesis drugs market due to the increasing frequency of diabetic gastroparesis caused by the global increase in the prevalence of diabetes, especially type 1 and type 2 diabetes. The prevalence of gastroparesis is predicted to rise along with the global rate of diabetes, especially as a result of aging populations and changing lifestyles. The increasing number of instances of diabetic gastroparesis is driving up demand for efficient symptom management and better patient outcomes. As a result, the market is providing fresh treatment choices to meet the unmet medical requirements of those with this crippling illness.
For instance, in June 2021 Evoke Pharma Announced the Issuance of a New U.S. Patent Covering Methods of Use for Gimoti. Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020.
Source:(https://investor.evokepharma.com/news-releases/news-release-details/evoke-pharma-announces-issuance-new-us-patent-covering-methods)
For instance, in July 2022, Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis, announced that the Canadian Intellectual Property Office granted the company a key patent for its previously submitted application (CA 2984736). The received patent is for GIMOTI's method of use.
Source:(https://investor.evokepharma.com/news-releases/news-release-details/evoke-pharma-expands-ip-portfolio-addition-canadian-patent)
- Diabetic Gastroparesis
- Post-Surgical Gastroparesis
- Idiopathic Gastroparesis
- Other Disease Types
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the gastroparesis drugs market, it can be concluded that the market for gastroparesis drugs worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Gastroparesis Drugs Market
In December 2023 – Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced that the FDA has accepted the filing of Vanda’s New Drug Application (NDA) for precipitant. Tradipitant is intended to be used for treating symptoms of gastroparesis.
Source:(https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-that-u.s.-food-and-drug-administration-accepts-new)
In February 2023, Renexxion Ireland announced the start of a Phase IIb trial of gastroparesis therapy. This trial has been mainly designed to assess the safety, tolerability, and efficacy of naronapride among gastroparesis patients. It will further help in the development of new drugs for gastroparesis.
Source:(https://www.clinicaltrialsarena.com/news/renexxion-ireland-gastroparesis-therapy/)
In December 2022, Evoke Pharma, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a United States Patent No. 11,517,545 under the title 'Treatment of Moderate and Severe Gastroparesis'' which covers the usage of GIMOTI.
Source:(https://www.biospace.com/article/releases/uspto-grants-new-patent-to-evoke-pharma-covering-the-usage-of-gimoti-to-treat-moderate-to-severe-gastroparesis/)
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Gastroparesis Drugs Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Type | Antiemetic Agents, Prokinetic Agents, Botulinum Toxin Injections |
| End-User | Hospitals, Clinics, Pharmacies |
| Disease Type | Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types |
| List of Competitors | Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc., Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc |
This chapter will help you gain GLOBAL Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review Global Gastroparesis Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Gastroparesis Drugs Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Gastroparesis Drugs Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Gastroparesis Drugs Revenue Market Size By Region
-
-
1.3 Global Gastroparesis Drugs Market Size By Drug Type 2019 -2031
-
1.3.1 Antiemetic Agents Market Size
-
1.3.2 Prokinetic Agents Market Size
-
1.3.3 Botulinum Toxin Injections Market Size
-
-
1.4 Global Gastroparesis Drugs Market Size By End-User 2019 -2031
-
1.4.1 Hospitals Market Size
-
1.4.2 Clinics Market Size
-
1.4.3 Pharmacies Market Size
-
-
1.5 Global Gastroparesis Drugs Market Size By Disease Type 2019 -2031
-
1.5.1 Diabetic Gastroparesis Market Size
-
1.5.2 Post-Surgical Gastroparesis Market Size
-
1.5.3 Idiopathic Gastroparesis Market Size
-
1.5.4 Other Disease Types Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Type
-
1.7.3 Global Market Revenue Split By End-User
-
1.7.4 Global Market Revenue Split By Disease Type
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review North America Gastroparesis Drugs Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Gastroparesis Drugs Market Size 2019 - 2031
-
2.1.1 North America Gastroparesis Drugs Market Size By Country 2019 - 2031
-
2.1.2 North America Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
2.1.2.1 North America Antiemetic Agents Market Size
-
2.1.2.2 North America Prokinetic Agents Market Size
-
2.1.2.3 North America Botulinum Toxin Injections Market Size
-
-
2.1.3 North America Gastroparesis Drugs Market Size by End-User 2019 -2031
-
2.1.3.1 North America Hospitals Market Size
-
2.1.3.2 North America Clinics Market Size
-
2.1.3.3 North America Pharmacies Market Size
-
-
2.1.4 North America Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
2.1.4.1 North America Diabetic Gastroparesis Market Size
-
2.1.4.2 North America Post-Surgical Gastroparesis Market Size
-
2.1.4.3 North America Idiopathic Gastroparesis Market Size
-
2.1.4.4 North America Other Disease Types Market Size
-
-
This chapter will help you gain Europe Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review Europe Gastroparesis Drugs Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Gastroparesis Drugs Market Size 2019 - 2031
-
3.1.1 Europe Gastroparesis Drugs Market Size By Country 2019 - 2031
-
3.1.2 Europe Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
3.1.2.1 Europe Antiemetic Agents Market Size
-
3.1.2.2 Europe Prokinetic Agents Market Size
-
3.1.2.3 Europe Botulinum Toxin Injections Market Size
-
-
3.1.3 Europe Gastroparesis Drugs Market Size by End-User 2019 -2031
-
3.1.3.1 Europe Hospitals Market Size
-
3.1.3.2 Europe Clinics Market Size
-
3.1.3.3 Europe Pharmacies Market Size
-
-
3.1.4 Europe Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
3.1.4.1 Europe Diabetic Gastroparesis Market Size
-
3.1.4.2 Europe Post-Surgical Gastroparesis Market Size
-
3.1.4.3 Europe Idiopathic Gastroparesis Market Size
-
3.1.4.4 Europe Other Disease Types Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review Asia Pacific Gastroparesis Drugs Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Gastroparesis Drugs Market Size 2019 - 2031
-
4.1.1 Asia Pacific Gastroparesis Drugs Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
4.1.2.1 Asia Pacific Antiemetic Agents Market Size
-
4.1.2.2 Asia Pacific Prokinetic Agents Market Size
-
4.1.2.3 Asia Pacific Botulinum Toxin Injections Market Size
-
-
4.1.3 Asia Pacific Gastroparesis Drugs Market Size by End-User 2019 -2031
-
4.1.3.1 Asia Pacific Hospitals Market Size
-
4.1.3.2 Asia Pacific Clinics Market Size
-
4.1.3.3 Asia Pacific Pharmacies Market Size
-
-
4.1.4 Asia Pacific Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
4.1.4.1 Asia Pacific Diabetic Gastroparesis Market Size
-
4.1.4.2 Asia Pacific Post-Surgical Gastroparesis Market Size
-
4.1.4.3 Asia Pacific Idiopathic Gastroparesis Market Size
-
4.1.4.4 Asia Pacific Other Disease Types Market Size
-
-
This chapter will help you gain South America Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review South America Gastroparesis Drugs Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Gastroparesis Drugs Market Size 2019 - 2031
-
5.1.1 South America Gastroparesis Drugs Market Size By Country 2019 - 2031
-
5.1.2 South America Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
5.1.2.1 South America Antiemetic Agents Market Size
-
5.1.2.2 South America Prokinetic Agents Market Size
-
5.1.2.3 South America Botulinum Toxin Injections Market Size
-
-
5.1.3 South America Gastroparesis Drugs Market Size by End-User 2019 -2031
-
5.1.3.1 South America Hospitals Market Size
-
5.1.3.2 South America Clinics Market Size
-
5.1.3.3 South America Pharmacies Market Size
-
-
5.1.4 South America Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
5.1.4.1 South America Diabetic Gastroparesis Market Size
-
5.1.4.2 South America Post-Surgical Gastroparesis Market Size
-
5.1.4.3 South America Idiopathic Gastroparesis Market Size
-
5.1.4.4 South America Other Disease Types Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Gastroparesis Drugs. Further deep in this chapter, you will be able to review Middle East and Africa Gastroparesis Drugs Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Gastroparesis Drugs Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Gastroparesis Drugs Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
6.1.2.1 Middle East and Africa Antiemetic Agents Market Size
-
6.1.2.2 Middle East and Africa Prokinetic Agents Market Size
-
6.1.2.3 Middle East and Africa Botulinum Toxin Injections Market Size
-
-
6.1.3 Middle East and Africa Gastroparesis Drugs Market Size by End-User 2019 -2031
-
6.1.3.1 Middle East and Africa Hospitals Market Size
-
6.1.3.2 Middle East and Africa Clinics Market Size
-
6.1.3.3 Middle East and Africa Pharmacies Market Size
-
-
6.1.4 Middle East and Africa Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
6.1.4.1 Middle East and Africa Diabetic Gastroparesis Market Size
-
6.1.4.2 Middle East and Africa Post-Surgical Gastroparesis Market Size
-
6.1.4.3 Middle East and Africa Idiopathic Gastroparesis Market Size
-
6.1.4.4 Middle East and Africa Other Disease Types Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Gastroparesis Drugs Market Size by Drug Type 2019 -2031
-
7.1.2 Country 1Gastroparesis Drugs Market Size by End-User 2019 -2031
-
7.1.3 Country 1Gastroparesis Drugs Market Size by Disease Type 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Gastroparesis Drugs. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Gastroparesis Drugs Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Medtronic
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Kimberly-Clark Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Abbott Laboratories
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Salix Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Boston Scientific Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 C. R. Bard
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Janssen Global Services LLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Cardinal Health
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Alfa Wassermann SPA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Evoke Pharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Rhythm Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Kimberly-Clark Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 Abbott Laboratories
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
8.2.18 Salix Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.18.2 Business Overview
-
8.2.18.3 Financials (Subject to data availability)
-
8.2.18.4 Product Types Specification
-
8.2.18.5 Business Strategy
-
8.2.18.6 S.W.O.TAnalysis
-
-
8.2.19 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.19.2 Business Overview
-
8.2.19.3 Financials (Subject to data availability)
-
8.2.19.4 Product Types Specification
-
8.2.19.5 Business Strategy
-
8.2.19.6 S.W.O.TAnalysis
-
-
8.2.20 Boston Scientific Corporation
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.20.2 Business Overview
-
8.2.20.3 Financials (Subject to data availability)
-
8.2.20.4 Product Types Specification
-
8.2.20.5 Business Strategy
-
8.2.20.6 S.W.O.TAnalysis
-
-
8.2.21 C. R. Bard
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.21.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.21.2 Business Overview
-
8.2.21.3 Financials (Subject to data availability)
-
8.2.21.4 Product Types Specification
-
8.2.21.5 Business Strategy
-
8.2.21.6 S.W.O.TAnalysis
-
-
8.2.22 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.22.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.22.2 Business Overview
-
8.2.22.3 Financials (Subject to data availability)
-
8.2.22.4 Product Types Specification
-
8.2.22.5 Business Strategy
-
8.2.22.6 S.W.O.TAnalysis
-
-
8.2.23 Janssen Global Services LLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.23.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.23.2 Business Overview
-
8.2.23.3 Financials (Subject to data availability)
-
8.2.23.4 Product Types Specification
-
8.2.23.5 Business Strategy
-
8.2.23.6 S.W.O.TAnalysis
-
-
8.2.24 Cardinal Health
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.24.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.24.2 Business Overview
-
8.2.24.3 Financials (Subject to data availability)
-
8.2.24.4 Product Types Specification
-
8.2.24.5 Business Strategy
-
8.2.24.6 S.W.O.TAnalysis
-
-
8.2.25 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.25.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.25.2 Business Overview
-
8.2.25.3 Financials (Subject to data availability)
-
8.2.25.4 Product Types Specification
-
8.2.25.5 Business Strategy
-
8.2.25.6 S.W.O.TAnalysis
-
-
8.2.26 Alfa Wassermann SPA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.26.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.26.2 Business Overview
-
8.2.26.3 Financials (Subject to data availability)
-
8.2.26.4 Product Types Specification
-
8.2.26.5 Business Strategy
-
8.2.26.6 S.W.O.TAnalysis
-
-
8.2.27 Evoke Pharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.27.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.27.2 Business Overview
-
8.2.27.3 Financials (Subject to data availability)
-
8.2.27.4 Product Types Specification
-
8.2.27.5 Business Strategy
-
8.2.27.6 S.W.O.TAnalysis
-
-
8.2.28 Rhythm Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.28.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.28.2 Business Overview
-
8.2.28.3 Financials (Subject to data availability)
-
8.2.28.4 Product Types Specification
-
8.2.28.5 Business Strategy
-
8.2.28.6 S.W.O.TAnalysis
-
-
8.2.29 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.29.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.29.2 Business Overview
-
8.2.29.3 Financials (Subject to data availability)
-
8.2.29.4 Product Types Specification
-
8.2.29.5 Business Strategy
-
8.2.29.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Drug Type Analysis 2019 -2031, will provide market size split by Drug Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Type Analysis 2019 -2031
-
10.1 Antiemetic Agents
-
10.1.1 Global Gastroparesis Drugs Revenue Market Size and Share by Antiemetic Agents 2019 -2031
-
-
10.2 Prokinetic Agents
-
10.2.1 Global Gastroparesis Drugs Revenue Market Size and Share by Prokinetic Agents 2019 -2031
-
-
10.3 Botulinum Toxin Injections
-
10.3.1 Global Gastroparesis Drugs Revenue Market Size and Share by Botulinum Toxin Injections 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by End-User Analysis 2019 -2031
-
11.1 Hospitals
-
11.1.1 Global Gastroparesis Drugs Revenue Market Size and Share by Hospitals 2019 - 2031
-
-
11.2 Clinics
-
11.2.1 Global Gastroparesis Drugs Revenue Market Size and Share by Clinics 2019 - 2031
-
-
11.3 Pharmacies
-
11.3.1 Global Gastroparesis Drugs Revenue Market Size and Share by Pharmacies 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Disease Type Analysis 2019 -2031
-
12.1 Diabetic Gastroparesis
-
12.1.1 Global Gastroparesis Drugs Revenue Market Size and Share by Diabetic Gastroparesis 2019 -2031
-
-
12.2 Post-Surgical Gastroparesis
-
12.2.1 Global Gastroparesis Drugs Revenue Market Size and Share by Post-Surgical Gastroparesis 2019 -2031
-
-
12.3 Idiopathic Gastroparesis
-
12.3.1 Global Gastroparesis Drugs Revenue Market Size and Share by Idiopathic Gastroparesis 2019 -2031
-
-
12.4 Other Disease Types
-
12.4.1 Global Gastroparesis Drugs Revenue Market Size and Share by Other Disease Types 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Gastroparesis Drugs market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Gastroparesis Drugs Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Gastroparesis Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Gastroparesis Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Gastroparesis Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Gastroparesis Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Gastroparesis Drugs Market
Key Questions Answered By Gastroparesis Drugs Market Report 2024
| Why Antiemetic Agents have a significant impact on Gastroparesis Drugs market? |
| What are the key factors affecting the Antiemetic Agents and Prokinetic Agents of Gastroparesis Drugs Market? |
| What is the CAGR/Growth Rate of Hospitals during the forecast period? |
| By type, which segment accounted for largest share of the global Gastroparesis Drugs Market? |
| Which region is expected to dominate the global Gastroparesis Drugs Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
